Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Cash & Equivalents (2023 - 2025)

Telix Pharmaceuticals has reported Cash & Equivalents over the past 3 years, most recently at $141.9 million for Q4 2025.

  • Quarterly Cash & Equivalents fell 69.46% to $141.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $141.9 million through Dec 2025, down 69.46% year-over-year, with the annual reading at $141.9 million for FY2025, 67.76% down from the prior year.
  • Cash & Equivalents was $141.9 million for Q4 2025 at Telix Pharmaceuticals, down from $464.5 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $464.5 million in Q4 2024 and troughed at $80.2 million in Q4 2023.
  • The 3-year median for Cash & Equivalents is $141.9 million (2025), against an average of $228.9 million.
  • Year-over-year, Cash & Equivalents skyrocketed 479.03% in 2024 and then tumbled 69.46% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $80.2 million in 2023, then skyrocketed by 479.03% to $464.5 million in 2024, then tumbled by 69.46% to $141.9 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Cash & Equivalents are $141.9 million (Q4 2025), $464.5 million (Q4 2024), and $80.2 million (Q4 2023).